推动epNEC诊疗规范化：从精准诊断到临床转化的路径思考

*仅供医学专业人士阅读参考

形态、标志物与分子特征协同，助力epNEC诊疗迈向精准诊疗新阶段

*以下内容仅供医疗卫生专业人士浏览。

参考文献：

[1]Rindi G, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms[J]. Endocrine pathology, 2022, 33(1): 115-154.

[2]Dasari A, et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases[J]. Cancer, 2018, 124(4): 807-815.

[3]Zeng X, et al. The challenge of diagnosing neuroendocrine neoplasms: experience from a national reference center[J]. Virchows Archiv, 2024: 1-11.

[4]中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）神经内分泌肿瘤诊疗指南 2024[M]. 北京 ：人民卫生出版社， 2024.

[5]Centonze G, Maisonneuve P, Prinzi N, et al. Prognostic factors across poorly differentiated neuroendocrine neoplasms: a pooled analysis[J]. Neuroendocrinology, 2023, 113(4): 457-469.

[6]Lozada J R, et al. Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting[J]. Cancer Research Communications, 2025, 5(2): 318-326.

SC-CN-17834

*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场。